Colon cancer treatment is personalized based on stage, overall health and tumor characteristics. Early detection and accurate ...
Postoperative circulating tumor DNA (ctDNA) positivity strongly predicts worse survival in stage III colon cancer, with ctDNA-positive patients showing sixfold higher recurrence risk. Among ...
Stage 3 colorectal cancer patients with MRD benefit from Celebrex addition to chemotherapy, showing a 40% risk reduction in death for Signatera-positive patients. Celebrex improved disease-free and ...
Innovent Biologics has received China’s National Medical Products Administration (NMPA) approval for the New Drug Application ...
This dual-immunotherapy neoadjuvant treatment regimen is mainly intended for patients with resectable stage IIB to III colon ...
From a young age, Katelyn Jonozzo took pride in being very active. Up until she was 18, she practiced gymnastics 4 to 5 days a week. "I loved the discipline, I loved having a regimented schedule," ...